论文部分内容阅读
目的 观察细胞色素450 1A1(CYP1A1)的基因多态性和多西他赛联合卡培他滨治疗转移性乳腺癌疗效的相关性.方法 入选69例接受多西他赛联合卡培他滨方案治疗的转移性乳腺癌(MBC)患者,同时对CYP450基因上最小等位基因频率(MAF)≥10％的79个多态性位点进行基因分型.对rs1048943(Ile462Val)单核苷酸多态性(SNP)位点和治疗反应率及预后的相关性进行分析.结果 发现仅CYP1A1的rs1048943 (Ile462Val)与无进展生存期(PVS)显著相关,GA/GG型患者与野生型AA型患者中位的PFS分别为8.3个月(95％ CI:5.4～11.8)和5.3个月(95％ CI:2.9 ～7.6),差异有统计学统计学意义(P＜0.05).纳入多变量校正模型(COx)当中校正之后,发现该位点是影响PFS独立的预测指标(HR =0.4,P＜0.05).结论 CYP1A1上的多态性位点rs1048943 (Ile462Val)可能是多西他赛联合卡培他滨方案治疗的转移性乳腺癌患者的一个可以预测预后的独立指标.“,”Objective To investigate the association between cytochrome P (CYP) 1A1 polymorphism and clinical outcomes in metastatic breast cancer (MBC) patients treated by docetaxel plus capecitabine.Methods Sixty-nine MBC patients who were treated with docetaxel plus capecitabine were included in this study.And 79 single nucleotide poly morphisms (SNPs) in CYP450,whose minor allele frequency (MAF) ≥ 10％ were genotyped.Association between rs1048943 (Ile462Val) and clinical outcomes were analyzed.Results Only one SNP,CYP1A1 rs1048943 was sigrnificantly associated with progress free survival (PFS),the median PFS of GA/GG genotype patients and wild type AA genotype patients were 8.3 months (95 ％ CI:5.4-11.8) and 5.3 months (95％ CI:2.9-7.6),with significant difference (P ＜0.05).Multivariate analysis conrirmed its prognostic significance for PFS (HR =0.4,P ＜ 0.05).Conclusion CYP1A1 rs1048943 polymorphism is probably a potential prognostic marker for survival outcomes treated with docetaxel plus capecitabine chemotherapy in MBC patients.